Eli Lilly and Company (NYSE:LLY) Announces Earnings Results

Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings results on Thursday. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.68 by $1.80, FiscalAI reports. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period in the prior year, the firm earned $7.02 earnings per share. The firm’s revenue was up 38.6% compared to the same quarter last year.

Here are the key takeaways from Eli Lilly and Company’s conference call:

• Q3 revenue rose 39% to approximately $24 billion, driven by Mounjaro, Zepbound, and broad strength across oncology, immunology, and neuroscience. Lilly raised its 2026 guidance to $91–$92 billion in revenue and $35–$36 in non-GAAP EPS.
• The incretin franchise continued to accelerate, with Mounjaro and Zepbound generating more than $16 billion in combined quarterly revenue. The Medicare GLP-1 Bridge Program has served more than 500,000 prescriptions, with seven in 10 new bridge patients choosing a Lilly obesity medicine.
• Lilly reported encouraging pipeline and regulatory progress, including strong retatrutide results versus semaglutide, positive data for the eloralintide/tirzepatide combination, and U.S. approvals for weekly basal insulin Onswik, expanded pirtobrutinib use, and new tirzepatide and imlunestrant indications.
• Pricing remains a significant headwind, with U.S. realized price declining 10% excluding a favorable rebate adjustment, while expanded Medicare and Medicaid access and self-pay growth are expected to pressure net price per prescription in 2027. Management also cautioned that roughly $2 billion of 2026 one-time benefits will not recur next year.
• Lilly is investing heavily for long-term growth, breaking ground on $11.5 billion of new U.S. manufacturing capacity and adding pipeline assets through the AtaiBeckley and Merida acquisitions, while maintaining a broad set of late-stage programs across oncology, neuroscience, and immunology.

Eli Lilly and Company Price Performance

LLY stock traded up $83.71 during midday trading on Thursday, hitting $1,372.01. The company’s stock had a trading volume of 4,351,588 shares, compared to its average volume of 2,933,143. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 12 month low of $812.25 and a 12 month high of $1,408.38. The company has a 50 day moving average of $1,192.52 and a two-hundred day moving average of $1,089.35. The firm has a market capitalization of $1.29 trillion, a price-to-earnings ratio of 46.04, a price-to-earnings-growth ratio of 1.71 and a beta of 0.46.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is 23.22%.

Analyst Upgrades and Downgrades

A number of analysts have commented on LLY shares. Guggenheim raised their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. Morgan Stanley increased their price target on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Truist Financial raised their price target on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a report on Friday, August 7th. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a report on Friday, August 7th. Finally, Leerink Partners raised their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,320.25.

Insider Activity

In other Eli Lilly and Company news, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 over the last 90 days. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong earnings and revenue beat: Third-quarter revenue rose 39% year over year to $24.4 billion, above the roughly $22.6 billion analyst estimate. Adjusted EPS was $7.48, well ahead of the $5.68 consensus and up from $7.02 a year earlier. Reuters earnings and outlook article
• Positive Sentiment: Higher full-year outlook: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion, lifting the midpoint by $5.5 billion. The increase signals that demand for its metabolic-care portfolio is exceeding prior expectations. Lilly third-quarter results and guidance
• Positive Sentiment: Mounjaro and Zepbound remain major growth engines: Mounjaro sales jumped 65% to $10.7 billion, while Zepbound revenue increased 49% to $5.35 billion. The results reinforced investor confidence in Lilly’s leadership of the diabetes and obesity-drug market. New York Post weight-loss drug demand article
• Positive Sentiment: Pipeline momentum improved: Phase 3 data showed experimental drug retatrutide produced greater A1C reduction and more than twice the weight loss of Ozempic 2 mg in adults with type 2 diabetes. The data strengthen Lilly’s competitive position against Novo Nordisk and support longer-term growth expectations. Lilly retatrutide trial results
• Neutral Sentiment: Investors should watch earnings quality: Quarterly revenue benefited from approximately $900 million in Jardiance milestones and rebate-related adjustments. Lilly also recorded substantial acquired in-process research and development charges, while reports noted a trimmed profit view tied to deal-related costs.
• Negative Sentiment: Insider selling is a secondary risk signal: Four Lilly executives sold shares during the past six months, with no reported open-market purchases. These transactions have not outweighed the earnings-driven optimism but may draw attention given the stock’s elevated valuation.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.